DOCSLIB.ORG

Mechanisms of Atrial Fibrillation Areas of Consensus Patient Selection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanisms of Atrial Fibrillation Areas of Consensus Patient Selection Mechanisms of Atrial Fibrillation Patient Selection Patient Selection for AF Ablation Shown in the table are some of the many Estimated Outcomes and Risks of AF Ablation The estimates provided on this table A B C D More Less variables which may impact patient selection Single Multiple are not based on the outcomes of large Optimal Patient Optimal Patient for catheter ablation of AF, either because Success Procedure Procedures prospective multicenter clinical trials. Variable they impact patient outcomes or they reflect Optimal patient 60% - 80% 80% - 90% These estimates are based on a review of Symptoms highly minimally symptomatic symptomatic the severity of the patient’s symptoms and Less optimal patient 50% - 70% 70% - 80% the published literature. It is recognized response to antiarrhythmic drug therapy. It is that the outcomes of AF ablation depend Class 1 and 3 drugs failed ≥ 1 0 Poor candidate < 40% 40% - 60% important to recognize that there are no ab- on a large number of variables including longstanding AF type paroxysmal solute cut-offs to determine which patients those shown in the table. In addition, the persistent Major complication rates: 2% - 12% are and are not candidates for AF ablation. technique and tools used may also impact Age younger (< 70 yrs) older ( ≥ 70 yrs) Left atrial flutter 2% - 5% Although this table has suggested certain outcomes. And finally, the experience of Vascular/access related 1% - 5% LA size smaller (< 5 cm) larger ( ≥ 5 cm) age and left atrial size cut-offs to determine the operator and of the ablation center at Cardiac tamponade 0.5% - 3% Structure and Shown in the Figure is a schematic drawing of the left and right atria as viewed from Ejection fraction normal reduced which patients are better candidates for AF which the procedure is performed also the posterior. The extension of muscular fibers onto the PVs can be appreciated. In Congestive Stroke 0.5% - 2% Mechanisms of no yes ablation, these are estimates and are not impact success and complication rates. heart failure Atrial Fibrillation yellow are the four major left atrial autonomic ganglionic plexi and axons (superior based on large prospective clinical trials. PV stenosis < 1% left, inferior left, anterior right, and inferior right). In blue is the coronary sinus which Other cardiac disease no yes The only absolute contraindications for AF Phrenic nerve injury < 0.5% is enveloped by muscular fibers which have connections to the atria. Also in blue is Pulmonary disease no yes ablation identified by the consensus writ- Adapted from Circulation, Esophageal perforation < 0.2% the vein and ligament of Marshall which travels from the coronary sinus to the region ing group were the presence of a left atrial Am J Cardiol, Tex Heart Inst J Sleep apnea no yes Mitral valve entrapment < 0.1% between the left superior PV and the left atrial appendage. thrombus or the inability of a patient to be Obesity no yes Acute coronary occlusion < 0.1% B: the large and small reentrant wavelets that play a role in initiating and systemically anticoagulated during and fol- Prior stroke/TIA no yes Death < 0.1% sustaining AF. lowing the ablation procedure. C: the common locations of PV (red) and also the common sites of origin of non PV triggers (shown in green). D: a composite of the anatomic and arrhythmic mechanisms of AF. Areas of Consensus Indications for Surgical AF Ablation n If additional linear lesions are applied, line com- Follow-up and Clinical Trial Considerations A B C D Definitions, Indications, pleteness should be demonstrated by mapping or Abalation Techniques n Symptomatic AF patients undergoing other cardiac Blanking Period pacing maneuvers. surgery. n A blanking period of three months should be em- n Ablation of the cavotricuspid isthmus is recom- AF Definition n Selected asymptomatic AF patients undergoing ployed after ablation when reporting outcomes. cardiac surgery in whom the ablation can be performed mended only in patients with a history of typical n Paroxysmal AF is defined as recurrent AF(> 2 episodes) with minimal risk. atrial flutter or inducible cavotricuspid isthmus Definition of Success that terminates spontaneously within seven days. dependent atrial flutter. n Stand-alone AF surgery should be considered for n Freedom from AF/flutter/tachycardia off antiarrhyth- n Persistent AF is defined as AF which is sustained symptomatic AF patients who prefer a surgical approach, n If patients with long-standing persistent AF are mic therapy is the primary endpoint of AF ablation. beyond seven days, or lasting less than seven days but approached, ostial PV isolation alone may not be have failed one or more attempts at catheter ablation, or n For research purposes, time to recurrence of AF necessitating pharmacologic or electrical cardioversion. sufficient. Schematic of Figure shows the circumferential ablation lesions, which are created in a circumfer- are not candidates for catheter ablation. following ablation is an acceptable end point after AF n Longstanding persistent AF is defined as continuous ential fashion around the right and the left PVs. The primary endpoint of this ablation ablation, but may under represent true benefit. Common Lesion Pre-procedure Management strategy is the electrical isolation of the PV musculature. AF of greater than one-year duration. Post Procedure Management Sets Employed n Freedom from AF at various points following ablation n The term permanent AF is not appropriate in the con- n Patients with persistent AF who are in AF at the time B: some of the most common sites of linear ablation lesions. These include a “roof may be a better marker of true benefit and should be in AF Ablation text of patients undergoing catheter ablation of AF as it of ablation should have a TEE performed to screen for Anticoagulation Strategies line” connecting the lesions encircling the left and and/or right PVs, a “mitral considered as a secondary endpoint of ablation. thrombus. isthmus” line connecting the mitral valve and the lesion encircling the left PVs at the refers to a group of patients where a decision has been n Heparin should be administered during AF ablation n Adapted from Circulation, Am J made not to pursue restoration of sinus rhythm by any Atrial flutter and other atrial tachyarrhythmias level of the left inferior PV, and an anterior linear lesion connecting either the “roof Ablation Techniques procedures to achieve and maintain an ACT of 300 to Cardiol, Tex Heart Inst J. should be considered as treatment failures. line” or the left or right circumferential lesion to the mitral annulus anteriorly. Also means, including catheter or surgical ablation. 400 sec. n Ablation strategies which target the PVs and/or n An episode of AF/flutter/tachycardia detected by shown is a linear lesion created at the cavotricuspid isthmus. This lesion is generally Indications for Catheter AF Ablation n Low molecular weight Heparin or intravenous PV antrum are the cornerstone for most AF ablation monitoring should be considered a recurrence if it has placed in patients who have experienced cavotricuspid isthmus dependent atrial Heparin should be used as a bridge to resumption of n Symptomatic AF refractory or intolerant to at least procedures. a duration of 30 seconds or more. flutter clinically or have it induced during EP testing. systemic anticoagulation following AF ablation. one Class 1 or 3 antiarrhythmic medication. n If the PVs are targeted, complete electrical isolation n Single procedure success should be reported in all C: the addition of additional linear ablation lesions between the superior and inferior n Coumadin is recommended for all patients for at n In rare clinical situations, it may be appropriate to should be the goal. PVs resulting in a figure of 8 lesion set. Also shown is an encircling lesion of the trials of catheter ablation of AF. perform AF ablation as first line therapy. least two months following an AF ablation procedure. superior vena cava directed at electrical isolation of the superior vena cava. SVC n For surgical PV isolation, entrance and/or exit block n Decisions regarding the use of Coumadin more than Repeat Procedures isolation is performed if focal firing from the SVC can be demonstrated. A subset of n Selected symptomatic patients with heart failure should be demonstrated. two months following ablation should be based on the n Repeat procedures should be delayed for at least operators empirically isolate the SVC. and/or reduced ejection fraction. n Careful identification of the PV ostia is mandatory to patient’s risk factors for stroke and not on the pres- three months following initial ablation, if the patient’s n The presence of a left atrial thrombus is a contra- avoid ablation within the PVs. D: some of the most common sites of ablation lesions when complex fractionated ence or type of AF. symptoms can be controlled with medical therapy. electrograms are targeted. indication to catheter ablation of AF. n If a focal trigger is identified outside a PV at the time n Discontinuation of Warfarin therapy post ablation of an AF ablation procedure, it should be targeted if is generally not recommended in patients who have a possible. CHADs score ≥ 2. Heart Rhythm Society Tel: (202) 464-3400 1400 K St NW, Suite 500 Fax: (202) 464-3401 SM Washington DC 20005 www.HRSonline.org SM Background Shown in the figure are some of the many During the past decade, catheter ablation of atrial fibrillationvariables (AF) which has mayevolved impact rapidly patient from selection for catheter ablation of AF, either because a highly experimental unproven procedure, to its current status as a commonly performed they impact patient outcomes or they reflect POCKet GUide 0 ablation procedure in many major hospitals throughout thethe severity world.
Load more

Recommended publications
  • 187977002.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano 339 Special Article Venice Chart International Consensus Document on Ventricular Tachycardia/Ventricular Fibrillation Ablation ANDREA NATALE, M.D.,∗ ANTONIO RAVIELE, M.D.,† AMIN AL-AHMAD, M.D.,‡ OTTAVIO ALFIERI, M.D.,¶ ETIENNE ALIOT, M.D.,∗∗ JESUS ALMENDRAL, M.D.,†† GUNTER¨ BREITHARDT, M.D.,‡‡ JOSEP BRUGADA, M.D.,¶¶ HUGH CALKINS, M.D.,∗∗∗ DAVID CALLANS, M.D.,††† RICCARDO CAPPATO, M.D.,‡‡‡ JOHN A. CAMM, M.D.,¶¶¶ PAOLO DELLA BELLA, M.D.,∗∗∗∗ GERARD M. GUIRAUDON, M.D.,†††† MICHEL HAISSAGUERRE,¨ M.D.,‡‡‡‡ GERHARD HINDRICKS, M.D.,¶¶¶¶ SIEW YEN HO, M.D.,∗∗∗∗∗ KARL H. KUCK, M.D.,††††† FRANCIS MARCHLINSKI, M.D.,‡‡‡‡‡ DOUGLAS L. PACKER, M.D.,¶¶¶¶¶ ERIC N. PRYSTOWSKY, M.D.,∗∗∗∗∗∗ VIVEK Y. REDDY, M.D.,†††††† JEREMY N. RUSKIN, M.D.,‡‡‡‡‡‡ MAURICIO SCANAVACCA, M.D.,¶¶¶¶¶¶ KALYANAM SHIVKUMAR, M.D.,∗∗∗∗∗∗∗ KYOKO SOEJIMA, M.D.,††††††† WILLIAM J. STEVENSON, M.D.,‡‡‡‡‡‡‡ SAKIS THEMISTOCLAKIS, M.D.,¶¶¶¶¶¶¶ ATUL VERMA, M.D.,∗∗∗∗∗∗∗∗ and DAVID WILBER, M.D.,†††††††† for the Venice Chart members From the ∗Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA; †Cardiovascular Department, Ospedale dell’Angelo, Mestre-Venice, Italy; ‡Cardiac Arrhythmia Service, Stanford University Medical School, Stanford, USA; ¶Department of Cardiac Surgery, Ospedale San Raffaele, Milan, Italy; ∗∗Department of Cardio-Vascular Diseases, CHU de Nancy, Hopitalˆ de Brabois, Vandoeuvre-les-Nancy, France; ††Division of Cardiology,
    [Show full text]
  • Catheter Ablation for Atrial Fibrillation - Project ID: CRDT0913
    Final Topic Refinement Document Catheter Ablation for Atrial Fibrillation - Project ID: CRDT0913 Date: 05/29/2014 Topic: Catheter Ablation for Atrial Fibrillation – Project ID: CRDT0913 EPC: Pacific Northwest EPC AHRQ Task Order Officer: Kim Wittenberg Partner: CMS 1 Final Topic Refinement Document Catheter Ablation for Atrial Fibrillation - Project ID: CRDT0913 Final Topic Refinement Document Key Questions In patients with longstanding persistent atrial fibrillation (AF), persistent AF, or paroxysmal AF (considered separately): Key Question 1. What is the comparative efficacy and effectiveness of AF catheter ablation on short- (6-12 months) and long- (>12 months) term outcomes in the general adult and Medicare populations? Comparisons of interest include: a) Catheter ablation compared with medical therapy b) Comparing ablation using different energy sources Key Question 2. What are the comparative short- and long-term complications and harms (e.g., periprocedural or device-related harms) associated with AF catheter ablation in the general adult and Medicare populations? Comparisons of interest include: a) Catheter ablation compared with medical therapy b) Comparing ablation using different energy sources Key Question 3. Are there modifications of efficacy, effectiveness, or harms of catheter ablation by patient-level characteristics such as age, sex, type of AF, comorbidities, risk for stroke or bleeding events, condition (i.e., patients with significant left ventricular dysfunction/heart failure or patients with significant left atrial enlargement or left ventricular hypertrophy), provider/setting characteristics or technique/approach? Comparisons of interest include: a) Catheter ablation compared with medical therapy b) Comparing ablation using different energy sources 2 Final Topic Refinement Document Catheter Ablation for Atrial Fibrillation - Project ID: CRDT0913 Draft Analytic Framework Figure 1.
    [Show full text]
  • Press Release Paris, May 2010
    Press Release Paris, May 2010 LEFOULON-DELALANDE FOUNDATION The 2010 Grand Prix Scientifique has been awarded to PROF. MICHEL HAÏSSAGUERRE Director of the Department of Cardiac Arrhythmia at the University Hospital of Bordeaux The Lefoulon-Delalande Foundation’s Grand Prix Scientifique , worth 500,000 Euros, is intended to reward a personality in the world of science who has made a significant scientific contribution to physiology, biology or cardiovascular medicine. The 2010 Grand Prix Scientifique has been awarded to the French research scientist, Michel Haïssaguerre, for his revolutionary discoveries in the field of cardiac arrhythmias and more particularly his work into the causes and treatment of atrial and ventricular fibrillations. This prize will make it possible to fund the creation of LIRYC – An Institute for Cardiac Rhythm Studies and Cardiac Modelling, a project in which Michel Haïssaguerre is one of the main initiators. This global institution, which is devoted to the study of electrical malfunctions of the heart, could allow - by pooling the skills of various European laboratories - major progress to be made and the number of people suffering from this pathology to be reduced by many thousands. The Prize will be awarded under the Cupola of the Institut de France On Wednesday, June 9th, 2010, at 3pm as will all the other scientific and cultural Grands Prix awarded by Institut de France foundations: The Christophe and Rodolphe Mérieux, Louis D., NRJ and Simone and Cino del Duca Foundations MICHEL HAÏSSAGUERRE Michel Haïssaguerre was born in 1955 in Bayonne (France). With a Master’s Degree in Human Biology, he obtained a PhD in Medicine in 1982.
    [Show full text]
  • Multidimensional Embedded MEMS Motion Detectors for Wearable Mechanocardiography and 4D Medical Imaging
    Multidimensional Embedded MEMS Motion Detectors for Wearable Mechanocardiography and 4D Medical Imaging Mojtaba Jafari Tadi TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS SARJA - SER. D OSA - TOM. 1404 | MEDICA - ODONTOLOGICA | TURKU 2018 30957047_Turun_yliopisto_Thesis_Mojtaba_Jafaritadi_Faculty_of_Medicine_cover_wire_18_11_26.indd 1 26.11.2018 12.18.12 MULTIDIMENSIONAL EMBEDDED MEMS MOTION DETECTORS FOR WEARABLE MECHANOCARDIOGRAPHY AND 4D MEDICAL IMAGING Mojtaba Jafari Tadi TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS SARJA - SER. D OSA - TOM. 1404 | MEDICA - ODONTOLOGICA | TURKU 2018 30957047_Turun_yliopisto_Thesis_Mojtaba_Jafaritadi_Faculty_of_Medicine_inside_18_11_26.indd 1 26.11.2018 8.11.17 University of Turku Faculty of Medicine Medical Physics and Engineering Doctoral Program in Clinical Research Turku PET Center, Turku University Hospital Abstract Faculty of Science and Engineering Department of Future Technologies Mojtaba Jafari Tadi, M.Sc. Supervised by University of Turku, Faculty of Medicine, Medical Physics and Engineering, Doctoral Program in Clinical Research, Associate Professor. Antti Saraste, MD, Ph.D. Professor Mika Teräs, Ph.D. Turku PET Center, Turku University Hospital, Department of Medical Physics Department of Cardiology, Faculty of Science and Engineering, Department of Future Technologies Department of Biomedicine Turku Heart Center University of Turku Turku PET Center Multidimensional Embedded MEMS Motion Detectors for Wearable Mechanocardio- Turku University Hospital University
    [Show full text]
  • 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial fibrillation
    2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation Hugh Calkins, MD (Chair),1 Gerhard Hindricks, MD (Vice-Chair),2,* Riccardo Cappato, MD (Vice-Chair),3,{ Young-Hoon Kim, MD, PhD (Vice-Chair),4,x Eduardo B. Saad, MD, PhD (Vice-Chair),5,z Luis Aguinaga, MD, PhD,6,z Joseph G. Akar, MD, PhD,7 Vinay Badhwar, MD,8,# Josep Brugada, MD, PhD,9,* John Camm, MD,10,* Peng-Sheng Chen, MD,11 Shih-Ann Chen, MD,12,x Mina K. Chung, MD,13 Jens Cosedis Nielsen, DMSc, PhD,14,* Anne B. Curtis, MD,15,k D. Wyn Davies, MD,16,{ John D. Day, MD,17 André d’Avila, MD, PhD,18,zz N.M.S. (Natasja) de Groot, MD, PhD,19,* Luigi Di Biase, MD, PhD,20,* Mattias Duytschaever, MD, PhD,21,* James R. Edgerton, MD,22,# Kenneth A. Ellenbogen, MD,23 Patrick T. Ellinor, MD, PhD,24 Sabine Ernst, MD, PhD,25,* Guilherme Fenelon, MD, PhD,26,z Edward P. Gerstenfeld, MS, MD,27 David E. Haines, MD,28 Michel Haissaguerre, MD,29,* Robert H. Helm, MD,30 Elaine Hylek, MD, MPH,31 Warren M. Jackman, MD,32 Jose Jalife, MD,33 Jonathan M. Kalman, MBBS, PhD,34,x Josef Kautzner, MD, PhD,35,* Hans Kottkamp, MD,36,* Karl Heinz Kuck, MD, PhD,37,* Koichiro Kumagai, MD, PhD,38,x Richard Lee, MD, MBA,39,# Thorsten Lewalter, MD, PhD,40,{ Bruce D. Lindsay, MD,41 Laurent Macle, MD,42,** Moussa Mansour, MD,43 Francis E. Marchlinski, MD,44 Gregory F.
    [Show full text]
  • DANA-DISSERTATION-2016.Pdf
    Copyright by Nicholas Pacheco Dana 2016 The Dissertation Committee for Nicholas Pacheco Dana Certifies that this is the approved version of the following dissertation: Photoacoustic Image Guidance and Tissue Characterization in Cardiovascular Applications Committee: Laura Suggs, Supervisor Stanislav Emelianov, Co-Supervisor Andrew Dunn James Tunnell Richard Bouchard Photoacoustic Image Guidance and Tissue Characterization in Cardiovascular Applications by Nicholas Pacheco Dana, B.S.; M.S.E. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin December 2016 Acknowledgements When work such as this comes to fruition, it is impossible acknowledge everyone who has made a worthy contribution. Still, the generosity of a several people stand out and deserve recognition. I’d like to thank the colleagues I’ve worked with in the various ultrasound and biomaterials labs incarnations. Your support and assistance, as well as your patience and tolerance of my incoherent mumblings in our shared workspace, cannot be overstated. I’d also like to thank Tera Sherrard and Marissa Canales, whose friendship and diligence allowed this work to continue. I’d like to thank Dr. Jason Cook, who has often been my unofficial mentor as I’ve stumbled along. I wish to thank Joshua Gray and Trevor Mitcham, for their help with work done far afield. For the inelegant composition before you, I’d like to thank Timothy Sowers, who has been a terrific boon composing this work. Of course, I owe much to my committee members, Dr.
    [Show full text]
  • Full Curriculum Vitae (CV)
    FULL CURRICULUM VITAE (C.V.) Name: Yoram Rudy Affiliation: Washington University in St Louis Title: The Fred Saigh Distinguished Professor of Engineering, Professor of Biomedical Engineering, Medicine, Cell Biology & Physiology, Radiology, and Pediatrics Director, Cardiac Bioelectricity and Arrhythmia Center (CBAC) Address: Washington University in St Louis Cardiac Bioelectricity Center 290 Whitaker Hall, Campus Box 1097 One Brookings Drive St Louis, MO 63130-4899, USA Phone: (314) 935-8160 FAX: (314) 935-8168 Email: [email protected] http://rudylab.wustl.edu http://cbac.wustl.edu Education: Technion, Haifa, Israel, B.Sc., 1971, Physics Technion, Haifa, Israel, M.Sc., 1973, Physics Case Western Reserve University, School of Medicine, 1 year, 1976 Case Western Reserve University, Ph.D., 1978, Biomedical Engineering 1 Professional (Research/Teaching) Experience: 2004 - Director, Cardiac Bioelectricity and Arrhythmia Center (CBAC) Washington University in St Louis 2004 - The Fred Saigh Distinguished Professor of Engineering, Professor of Biomedical Engineering, Medicine, Cell Biology & Physiology, Radiology, and Pediatrics Washington University in St Louis 2014 – 2020 Oxford University, Visiting Professor in Computational Medicine in the Mathematical, Physical and Life Sciences Division and the Department of Computer Science 1994 - 2004 Director, Cardiac Bioelectricity Research and Training Center (CBRTC) Case Western Reserve University, Cleveland, Ohio 2001 - 2004 The M. Frank and Margaret C. Rudy Professor of Cardiac Bioelectricity Case Western
    [Show full text]
  • AVC : Nouveautés Thérapeutiques
    AVC : nouveautés thérapeutiques Stroke: new therapies L’édition de cet ouvrage a été rendue possible grâce à l’Institut Servier. This publication has been made possible through an educational grant from the Institut Servier. L’éditeur ne pourra être tenu responsable de tout incident, tant aux personnes qu’aux biens, qui pourrait résulter soit de sa négligence, soit de l’utilisation de tous produits, méthodes, instructions ou idées décrits dans la publication. En raison de l’évolution rapide de la science médicale, l’éditeur recommande qu’une vérification intervienne pour les diagnostics et la posologie. The Publisher cannot be held responsible for any injury and/or damage to persons or property, which may result either from negligence or from the use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in medical sciences, the Publisher recom mends that independent verification of diagnoses and drug dosages should be made. © 2015 Springer Science + Business Media France Sarl. Tous droits réservés 22 Rue de Palestro 75002 Paris France Aucune partie de la présente publication ne peut être reproduite, diffusée ou enregistrée sous quelque forme ou par quelque moyen que ce soit, mécanique ou électronique, y compris par photocopie, enregistrement ou par des sys tèmes de stockage et de récupération de données, sans l’autorisation écrite de l’éditeur. No parts of this publication may be reproduced, transmitted or stored in any form or by any means, either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the publisher.
    [Show full text]
  • Ivabradine for Inappropriate Sinus Node Tachycardia
    Dear Colleagues, We are pleased to invite you to join us at the 9th Annual Scientific Congress of the European Cardiac Arrhythmia Society “ECAS” to be held in Paris, France April 14 to 16, 2013 at the Meridien-Etoile Hotel. All those who attended previous editions of ECAS Congress know that it is a highly scientific and educational event in a cheerful atmosphere which facilitates the interaction between the renowned faculty and younger colleagues in the field. This edition promises to be particularly successful and we will be delighted to welcome you in Paris. Gilles Lascault, MD Xavier Jouven, MD Riccardo Cappato, MD Congress Chairman Scientific Program Chair President of ECAS Executive Committee of the European Cardiac Arrhythmia Society President Riccardo Cappato (Milan, IT) Past President Wyn Davies (London, GB) Vice-President (Education & Research) Richard Hauer (Utrecht, NL) Vice-President (National Societies) Massimo Santini (Rome, IT) Vice-President (International Societies & EU) Samuel Lévy (Marseille, FR) Treasurers Eli Ovsyshcher (Beersheba, IL) Secretary General Leo Van Wersch (Paris, FR) Organizing Committee ECAS 2013 Riccardo Cappato, Xavier Copie, Fernand Hessel, Xavier Jouven, Ellen Hoffmann, Stefan Kaab, Gilles Lascault, Samuel Lévy (Chair), Michael Nabauer, Olivier Piot, Gerhard Steinbeck Gilles Lascault, MD S amuel Lévy, MD Gerhard Steinbeck, MD Program Committee Andrey Ardashev ; Alawi Alsheikh-Ali ; Serge Barold ; David S Cannom ; Riccardo Cappato ; Wyn Davies ; Roberto De Ponti ; Heidi Estner ; Jeronimo Farre ; Mark Estes III ; John Fisher; Robert Hatala ; Richard Hauer ; Ellen Hoffmann ; Charles Jazra ; Xavier Jouven (Chair) ; Stefan Kaab ; Jean-François Leclercq ; Gilles Lascault ; Samuel Lévy ; Thorsten Lewalter ; Shaowen Liu ; Peter Loh ; Pierpaolo Lupo ; Chang Sheng Ma ; Michael Nabauer ; Mohan Nair ; Yuji Nakazato ; Andrea Natale ; Petr Neuzil ; Eli Ovsyshcher ; Douglas L Packer ; Luigi Padeletti ; Nicholas S.
    [Show full text]
  • Mapping the Substrate of Atrial Fibrillation: Tools and Techniques Bryce Eric Benson University of Vermont
    University of Vermont ScholarWorks @ UVM Graduate College Dissertations and Theses Dissertations and Theses 2016 Mapping the Substrate of Atrial Fibrillation: Tools and Techniques Bryce Eric Benson University of Vermont Follow this and additional works at: https://scholarworks.uvm.edu/graddis Recommended Citation Benson, Bryce Eric, "Mapping the Substrate of Atrial Fibrillation: Tools and Techniques" (2016). Graduate College Dissertations and Theses. 634. https://scholarworks.uvm.edu/graddis/634 This Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact [email protected]. Mapping the Substrate of Atrial Fibrillation: Tools and Techniques A Dissertation Presented by Bryce E. Benson to The Faculty of the Graduate College of The University of Vermont In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Specializing in Bioengineering October, 2016 Defense Date: August 25th, 2016 Dissertation Examination Committee: Peter Spector, M.D., Advisor Jason Bates, Ph.D. Mary Dunlop, Ph.D. Margaret Eppstein, Ph.D., Chairperson Cynthia J. Forehand, Ph.D., Dean of Graduate College Abstract Atrial fibrillation (AF) is the most common cardiac arrhythmia that affects an estimated 33.5 million people worldwide. Despite its prevalence and economic burden, treatments remain relatively ineffective. Interventional treatments using catheter ablation have shown more success in cure rates than pharmacologic methods for AF. However, success rates diminish drastically in patients with more advanced forms of the disease. The focus of this research is to develop a mapping strategy to improve the suc- cess of ablation.
    [Show full text]
  • 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter
    2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society Hugh Calkins, MD, FACC, FHRS, FAHA; Karl Heinz Kuck, MD, FESC; Riccardo Cappato, MD, FESC; Josep Brugada, MD, FESC; A. John Camm, MD, PhD; Shih-Ann Chen, MD, FHRS§; ;Harry J.G. Crijns, MD, PhD, FESC; Ralph J. Damiano, Jr., MDٙ; D. Wyn Davies, MD, FHRS ;John DiMarco, MD, PhD, FACC, FHRS; James Edgerton, MD, FACC, FACS, FACCPٙ Kenneth Ellenbogen, MD, FHRS; Michael D. Ezekowitz, MD; David E. Haines, MD, FHRS; Michel Haissaguerre, MD; Gerhard Hindricks, MD; Yoshito Iesaka, MD§; Warren Jackman, MD, FHRS; Jose Jalife, MD, FHRS; Pierre Jais, MD; Jonathan Kalman, MD§; David Keane, MD; Young-Hoon Kim, MD, PhD§; Paulus Kirchhof, MD; George Klein, MD; Hans Kottkamp, MD; Koichiro Kumagai, MD, PhD§; Bruce D.
    [Show full text]
  • Volume I, Probing Mitochondrial Function M ETHODS in MOLECULAR BIOLOGY
    Methods in Molecular Biology 1264 Volkmar Weissig Marvin Edeas Editors Mitochondrial Medicine Volume I, Probing Mitochondrial Function M ETHODS IN MOLECULAR BIOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hat fi eld, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Mitochondrial Medicine Volume I, Probing Mitochondrial Function Edited by Volkmar Weissig Midwestern University, Glendale, AZ, USA Marvin Edeas ISANH, Paris, France Editors Volkmar Weissig Marvin Edeas Midwestern University ISANH Glendale , AZ , USA Paris , France ISSN 1064-3745 ISSN 1940-6029 (electronic) ISBN 978-1-4939-2256-7 ISBN 978-1-4939-2257-4 (eBook) DOI 10.1007/978-1-4939-2257-4 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2014960347 © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer.
    [Show full text]